RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. SPY
10. KNX

Go back to RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth

RedHill Biopharma (RDHL) Tops Q3 EPS by 21c, Revenues Miss

November 12, 2020 7:03 AM EST

RedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of $0.05, $0.21 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $25.37 million.

Financial highlights for the third quarter ended September 30, 20201

Net Revenues of $20.9 million, continuing at a similar level to that in the second quarter of 2020. The increase in gross revenues, as well as in the number of scripts for Talicia and Movantik, were partially offset by the voluntary discontinuation of our legacy products.Cost of Revenues of $10.3 million, compared to $14.2 million in the... More